CClinicalTrials.gg
RecruitingNCT07517796Updated Apr 8, 2026

I.V Papavrine for Labor Induction in Term PROM

A Phase 4 interventional study of Papaverine arm and Placebo in Premature Rupture of Membranes, sponsored by Western Galilee Hospital-Nahariya. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Western Galilee Hospital-Nahariya · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo

Read the detailed description

Prelabor rupture of membranes (PROM) at term complicates approximately 8% of pregnancies and is associated with increasing maternal and neonatal infectious morbidity as the latency period to delivery lengthens. Consequently, most clinical guidelines recommend active management with labor induction within 24 hours following membrane rupture. Cervical status at the time of induction plays a critical role in labor outcomes, and women with an unfavorable cervix, commonly defined as a Bishop score below 8, are at increased risk of prolonged labor and induction failure. The uterine cervix is composed primarily of connective tissue, with smooth muscle accounting for approximately 15% of its structure and concentrated mainly beneath the internal cervical os. Papaverine is a musculotropic antispasmodic agent that acts directly on smooth muscle, leading to reduced muscle spasm and enhanced relaxation. The pharmacokinetic profile of papaverine includes a rapid onset of action within approximately 10 minutes and a short half-life of 0.5-2 hours, making it a potentially suitable adjunct during early labor. Antispasmodic agents have been shown to accelerate cervical dilatation and shorten the first stage of labor; however, their role in the management of term PROM has not been systematically evaluated. We therefore aim to investigate whether intravenous administration of papaverine in women with term PROM shortens the interval from membrane rupture to delivery and improves cervical ripening and maternal and neonatal outcomes.

02

Conditions studied

  • Premature Rupture of Membranes

Keywords

  • premature rupture of membranes
  • papaverine
  • bishop score
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

    • Singleton pregnancy

      • Term gestation (37-42 weeks)
      • Term PROM prior to active labor
      • Duration of PROM \<12 hours at enrollment
      • Bishop score \<8
      • Cephalic presentation
      • Viable fetus with reassuring fetal heart rate

Exclusion criteria

Exclusion Criteria:

    • Multiple gestation

      • Previous cesarean delivery
      • Major fetal anomalies
      • Contraindication to vaginal delivery
      • Meconium-stained amniotic fluid
      • Suspected chorioamnionitis
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    papaverine arm

    IV-papaverine 80 mg in 100 ml 0.9% saline, once, 12 hours after rupture of membranes

    Drug: Papaverine arm

  • Placebo comparator
    Control arm

    I.V 100 ml 0.9% saline, 12 hours after rupture of membranes

    Other: Placebo

Interventions

  • DrugPapaverine arm

    given 12 houres after rupture of membranes

  • OtherPlacebo

    I.V seline

05

What researchers measure

Primary outcomes

  1. Time interval from rupture of membranes to delivery

    Time from rupture of membrane to delivery, measured in hours, including pre and post intervention periods

    Time frame: up to 5 days from rupture of membranes

Secondary outcomes

  1. change in bishop score following intervention

    Bishop score messured at admission and 18 houres after rupture of membranes, and comparing the delta bishop scores between the groups

    Time frame: baseline to 6-12 hours after intervention

  2. mode of delivary

    Mode of delivery categorized as vaginal (spontaneous or operative) or cesarean delivery

    Time frame: At delivery/birth

06

Study locations

1 of 1 sites recruiting
  • Galilee Medical Center
    Nahariya, Israel, Israel
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — The authors are willing to share the data of the study upon request of the Editors.

Supporting information: Study protocol, Icf, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07517796
Lead sponsor
Western Galilee Hospital-Nahariya
Responsible party
Dr. Maya Wolf (Head of Fetal Maternal Unit, Western Galilee Hospital-Nahariya) — Principal investigator
First posted
Apr 8, 2026
Start date
Oct 22, 2025
Primary completion
Oct 22, 2027 (estimated)
Completion
Oct 22, 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Maya Frank Wolf, professor
Contact
mayaw@gmc.gov.il
• 972:50-7887800

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion